Drug intelligence / Profile preview

OPT-600

Development stage: Preclinical
Lead developer: Oppilotech
Modality: Small Molecules
Administration: Oral

Overview

OPT-600 is a preclinical-stage antibacterial agent being developed by Oppilotech in partnership with Peptris. It is designed to target the isoprenoid biosynthesis pathway, a critical metabolic route in bacteria that is essential for the production of various cellular components, including those required for cell wall synthesis. The program specifically focuses on treating Gram-negative bacterial infections, aiming to address the significant unmet medical need posed by multi-drug resistant pathogens. As of 2024, the drug is in the discovery and preclinical development phase.

Targets

Bacterial isoprenoid biosynthesis enzymes

Beyond the preview

Go deeper on OPT-600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPT-600.

Explore the full profile